MEC Plus Full List ViewBy pinki@katapult.biz / February 16, 2025 MEC Plus Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignant Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Oral Cancer Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title Type of Media — Video Document Audio Events — 2024 California Cancer Consortium Conference (CCC) 2024 MCM 2024 MCM 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS 2024 MaTOS Lungs 2025 PRIMO Search Entries: Clear « 1 … 34 35 36 37 38 … 115 » Role of SHP2 Inhibitors Alone or in Combination Rachel Sanborn, MD View PDF Pan-KRAS Inhibitors: Where are We Going? Ferdinandos Skoulidis, MD View PDF KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors Karen Reckamp, MD View PDF KRAS mutant NSCLC: What is the Standard of Care Now? Mary Jo Fidler, MD View PDF RET and NTRK: The Good, The Bad, The Ugly.... and What’s Coming Up? John Heymach, MD View PDF ROS-1 & B-Raf Inhibitors: New Developments Julia Rotow, MD View PDF Mechanisms of Resistance to ALK Inhibitors Jessica Lin, MD View PDF ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent? Sai-Hong Ignatius Ou, MD, PhD View PDF Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC Luis E. Raez, MD View PDF Health Care Disparities in Lung Cancer Genomic Profiling Estelamari Rodriguez, MD View PDF Exon 20 and Uncommon EGFR Sensitive Mutations John Heymach, MD View PDF How to Rescue Patients from Osimertinib Resistance Wade T. Iams, MD, MSCI View PDF Best Approaches for First Line EGFR Mutant NSCLC Joshua Sabari, MD View PDF How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps? Mark Kris, MD View PDF What’s After PACIFIC? Can We Raise the Bar? Jhanelle Gray, MD View PDF Stage III Non-Surgical NSCLC: Optimal Radiation Therapy Approach Puneeth Iyengar, MD View PDF Stage III Non-Surgical Candidate NSCLC – Controversies in this Arena (Tumors with Actionable Genes and No PD-L1 Expression) Corey Langer, MD View PDF Best Surgical Approaches for Stage III NSCLC Jay M. Lee, MD View PDF Biomarkers for Perioperative Immunotherapy? David Carbone, MD View PDF MRD to Decide Perioperative Management in the Era of Immuno-Oncology Fred Hirsch, MD View PDF Adjuvant Immunotherapy Position Christina Baik, MD, MPH View PDF Neoadjuvant Immunotherapy Position Marina Garassino, MD View PDF Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going? Natasha Leighl, MD View PDF Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection Hatim Husain, MD View PDF Strategies to Target Minimal Residual Disease Christine M. Lovly, MD, PhD View PDF
